Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

The basis for the prevention of diabetic nephropathy is the treatment of its known risk factors: hypertension, hyperglycemia, smoking, and dyslipidemia. These are also risk factors for ...

05, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034 ... with diabetes eventually develop diabetic nephropathy or diabetes-related kidney disease.

Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. A detailed report forecasting the epidemiological trends of Idiopathic Membranous Nephropathy (IMN ...

Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy Demonstrated efficacy ...

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an ...

Palatin Technologies has announced topline results for the phase 2b Breakout study, which evaluated the effects of bremelanotide in patients with type 2 diabetic nephropathy. This condition is a ...

Lower levels of serum Podoplanin may predict diabetic nephropathy among diabetes patients suggests a study published in the Diabetes Metabolic Syndrome. The study aimed to investigate the impact of ...